Hemogenyx Pharmaceuticals PLC
HEMO
Company Profile
Business description
Hemogenyx Pharmaceuticals PLC is clinical-stage biotechnology focused on the discovery, development and commercialisation of innovative treatments relating to the treatment of blood cancers, certain solid cancers, autoimmune diseases, and viral infections. The products under development are designed to address a range of problems that occur with current standard of care treatments.
Contact
6 Heddon Street
LondonW1B 4BT
GBRSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
16
Stocks News & Analysis
stocks
Chart of the Week: Opportunities with wide-moat retailers
Consumer defensive names look undervalued.
stocks
New ASX share added to our best ideas
Earnings outlook is strong and the shares trade at a discount to our fair value.
stocks
Fair value downgraded for ASX heavyweight
Our capital allocation rating was also lowered due to balance sheet weakness.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,233.40 | 35.70 | 0.39% |
| CAC 40 | 7,966.95 | 71.01 | 0.90% |
| DAX 40 | 24,113.62 | 232.90 | 0.98% |
| Dow JONES (US) | 46,441.10 | 43.21 | 0.09% |
| FTSE 100 | 9,446.43 | 96.00 | 1.03% |
| HKSE | 27,214.59 | 359.03 | 1.34% |
| NASDAQ | 22,755.16 | 95.15 | 0.42% |
| Nikkei 225 | 44,831.32 | 280.47 | 0.63% |
| NZX 50 Index | 13,441.79 | 7.80 | 0.06% |
| S&P 500 | 6,711.20 | 22.74 | 0.34% |
| S&P/ASX 200 | 8,939.90 | 34.10 | 0.38% |
| SSE Composite Index | 3,882.78 | 20.25 | 0.52% |